A detailed history of Black Rock Inc. transactions in Xencor Inc stock. As of the latest transaction made, Black Rock Inc. holds 11,054,641 shares of XNCR stock, worth $209 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
11,054,641
Previous 11,323,310 2.37%
Holding current value
$209 Million
Previous $240 Million 1.77%
% of portfolio
0.01%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

SELL
$18.65 - $26.52 $5.01 Million - $7.13 Million
-268,669 Reduced 2.37%
11,054,641 $245 Million
Q4 2023

Feb 13, 2024

BUY
$16.53 - $21.42 $14.4 Million - $18.7 Million
873,507 Added 8.36%
11,323,310 $240 Million
Q3 2023

Nov 13, 2023

BUY
$20.08 - $25.39 $6.04 Million - $7.63 Million
300,631 Added 2.96%
10,449,803 $211 Million
Q2 2023

Aug 11, 2023

SELL
$24.77 - $29.9 $9.33 Million - $11.3 Million
-376,764 Reduced 3.58%
10,149,172 $253 Million
Q1 2023

May 12, 2023

SELL
$25.95 - $36.95 $3.17 Million - $4.52 Million
-122,231 Reduced 1.15%
10,525,936 $294 Million
Q4 2022

Feb 13, 2023

BUY
$24.79 - $30.86 $15.9 Million - $19.8 Million
641,201 Added 6.41%
10,648,167 $277 Million
Q3 2022

Nov 14, 2022

BUY
$24.62 - $32.44 $2.05 Million - $2.7 Million
83,291 Added 0.84%
10,006,966 $260 Million
Q2 2022

Aug 12, 2022

BUY
$19.74 - $29.01 $10.6 Million - $15.6 Million
538,458 Added 5.74%
9,923,675 $272 Million
Q1 2022

May 12, 2022

BUY
$26.68 - $41.63 $1.34 Million - $2.1 Million
50,387 Added 0.54%
9,385,217 $250 Million
Q4 2021

Feb 10, 2022

BUY
$33.67 - $43.44 $6.45 Million - $8.32 Million
191,467 Added 2.09%
9,334,830 $375 Million
Q3 2021

Nov 09, 2021

SELL
$30.65 - $35.68 $1.3 Million - $1.51 Million
-42,397 Reduced 0.46%
9,143,363 $299 Million
Q2 2021

Aug 11, 2021

BUY
$34.33 - $44.68 $315 Million - $410 Million
9,185,760 New
9,185,760 $317 Million

Others Institutions Holding XNCR

About Xencor Inc


  • Ticker XNCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,698,100
  • Market Cap $1.13B
  • Description
  • Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...
More about XNCR
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.